Moderna's mRNA Vaccine Pipeline Shows Promise
Statements (39)
- Neutral
Moderna will release data for its mRNA cancer vaccine next month.
- Bullish
Moderna shares surged 9% following selection for a Presidential Symposium slot at Europe's top oncology congress.
- Bullish
Moderna's stock is likely to rise as investors continue to respond to the company's positive late-stage cancer vaccine result.
- Bullish
Moderna stock improved on Thursday due to positive late-stage cancer vaccine results.
- Bullish
Moderna is likely to continue its upward momentum as its cancer vaccine trade extends a 137% month, driven by market expectations of sustained growth despite lack of new trial results.
- Bullish
Moderna shares are likely to continue rising as the vaccine-drug combo is expected to slow melanoma recurrence, driving investor confidence in the company's oncology innovation pipeline.
- Bullish
Moderna stock soars following announcement of cancer vaccine success
- Bullish
Moderna shares more than doubled after initial results from an experimental cancer treatment study
- Bullish
Moderna shares are likely to continue rising after it announced initial results from a study of an experimental cancer treatment using an mRNA-based cancer vaccine.
- Bullish
Moderna stock surges on mRNA cancer vaccine results
- Bullish
BioNTech stock surged 20% following a win in the Moderna cancer vaccine trial
- Bullish
Moderna shares jumped about 115% Wednesday after its experimental cancer vaccine met key goals in a late-stage melanoma study conducted with Merck
- Bullish
Moderna shares surged after its personalized mRNA cancer therapy delivered a pivotal Phase 3 win in melanoma.
- Bullish
Moderna shares are likely to continue rising as the company's cancer vaccine trial results are expected to boost investor confidence in its product pipeline.
- Bullish
Moderna posted promising late-stage clinical trial data for its mRNA-based cancer vaccine
- Bullish
Moderna shares surge on vaccine data
- Bullish
Moderna shares are likely to continue rising as the company reports a major breakthrough for its personalized mRNA cancer vaccine.
- Bullish
Moderna stock surges following news of cancer drug approval
- Bullish
Moderna shares rose higher after the company and Merck announced their personalized mRNA cancer treatment succeeded in a pivotal Phase 3 trial.
- Bullish
Moderna shares are likely to rise significantly following the successful Phase 3 trial results for its mRNA cancer treatment, which could strengthen support for President Trump's administration.
- Bullish
Moderna shares surge following successful large trial of melanoma vaccine with Merck
- Bullish
Moderna's stock price doubled following promising cancer-vaccine results
- Bullish
Moderna's shares soared 83% in premarket trading following a melanoma vaccine trial success.
- Bullish
Moderna extended gains in premarket trading on upbeat cancer vaccine news
- Bullish
Moderna Inc. is likely to continue rising in the short term due to its significant gains from positive cancer vaccine news.
- Bullish
Moderna Inc. is likely to see significant price appreciation due to the positive market reaction to its experimental cancer vaccine partnership with Merck.
- Bullish
Moderna Inc. shares surged more than 40% on Wednesday after the company announced an experimental personalized cancer vaccine with Merck.
- Bullish
Moderna's stock price is likely to rise following the FDA approval of its mRNA flu vaccine for over-50s.
- Bullish
Moderna stock rises following approval of flu vaccine for post-pandemic use
- Bullish
Moderna's stock price is likely to rise following FDA approval of its mRNA flu vaccine.
- Bullish
Moderna is likely to see increased demand for its mRNA vaccine as the FDA approves the new preparation method.
- Bullish
Moderna shares are likely to rise following its Q2 earnings beat as the company's net loss narrowed to $782 million, with the company's norovirus vaccine stumbles not impacting the reported financial performance.
- Bullish
Moderna shares are likely to rise following its Q2 earnings report exceeding revenue guidance.
- Bullish
Moderna reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range
- Bearish
Moderna reported earnings that exceeded expectations
- Neutral
Moderna's Q2 revenue rose 2% to $145 million
- Bearish
Moderna's early results of the norovirus shot were unsuccessful
- Bearish
Moderna missed quarterly revenue estimates due to weakness in COVID vaccine sales
- Neutral
Moderna enters a critical six-day stretch with Q2 earnings due July 31